High Dyspnea Score, a Trigger for Specialist Palliative Care Utilization-Results from a Cohort Study on the Predictors of High Opioid and Benzodiazepine Use in COVID-19 Patients.

IF 2.2 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Journal of palliative medicine Pub Date : 2024-11-26 DOI:10.1089/jpm.2024.0128
Lionel Kee Yon See, Mahrley Tanagon Provido, Sheryl Ng, Fionna Chunru Yow, Xin Lun Ho, Khar Suan Lee, Han Yee Neo, Oon Tek Ng, Kalisvar Marimuthu, Allyn Yin Mei Hum, Wen Yang Goh
{"title":"High Dyspnea Score, a Trigger for Specialist Palliative Care Utilization-Results from a Cohort Study on the Predictors of High Opioid and Benzodiazepine Use in COVID-19 Patients.","authors":"Lionel Kee Yon See, Mahrley Tanagon Provido, Sheryl Ng, Fionna Chunru Yow, Xin Lun Ho, Khar Suan Lee, Han Yee Neo, Oon Tek Ng, Kalisvar Marimuthu, Allyn Yin Mei Hum, Wen Yang Goh","doi":"10.1089/jpm.2024.0128","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> Patients with severe coronavirus disease 2019 (COVID-19) often rapidly deteriorate with severe dyspnea and should receive early specialist palliative care (SPC) as intensive symptom management may be required at the end of life. Currently, there is a paucity of data identifying triggers for early SPC involvement. <b><i>Objective</i>:</b> To identify risk factors among nonventilated patients with severe COVID-19 who required high opioid and/or benzodiazepines (BZD) use for the control of dyspnea. <b><i>Methods:</i></b> This is a retrospective cohort study of nonventilated patients with COVID-19 admitted to the National Centre for Infectious Diseases in Singapore and seen by SPC between January 2021 and July 2022. We collected baseline demographics, comorbidities, 4C mortality score (International Severe Acute Respiratory Infection Consortium-Comprehensive Clinical Characterization Collaboration [ISARIC-4C]), and COVID-19 vaccination status. Clinical and laboratory results, dyspnea by numerical rating scale, and palliative-related treatments were recorded at the first SPC review, when symptoms peaked, and the last SPC review. Patients with morphine equivalent daily dose (MEDD) of ≥45mg and/or BZD use for dyspnea control were grouped as high users, while patients with MEDD <45mg and no BZD use were low users. <b><i>Results:</i></b> Among 234 patients, 119 (50.9%) were high users. Multivariate analysis showed that subjects with higher dyspnea (odds ratio [OR] 1.74, 95% confidence interval [CI] 1.45-2.08) and lower ISARIC-4C scores (OR 0.77, 95% CI 0.67-0.88) at first SPC review were predictive of high users. High users also required higher supplemental oxygen and had higher inpatient mortality rates. <b><i>Conclusions:</i></b> High dyspnea score is predictive of high opioid and/or BZD use for symptom control in nonventilated patients with severe COVID-19. Such patients with high mortality rates should be seen early by SPC.</p>","PeriodicalId":16656,"journal":{"name":"Journal of palliative medicine","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of palliative medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/jpm.2024.0128","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Patients with severe coronavirus disease 2019 (COVID-19) often rapidly deteriorate with severe dyspnea and should receive early specialist palliative care (SPC) as intensive symptom management may be required at the end of life. Currently, there is a paucity of data identifying triggers for early SPC involvement. Objective: To identify risk factors among nonventilated patients with severe COVID-19 who required high opioid and/or benzodiazepines (BZD) use for the control of dyspnea. Methods: This is a retrospective cohort study of nonventilated patients with COVID-19 admitted to the National Centre for Infectious Diseases in Singapore and seen by SPC between January 2021 and July 2022. We collected baseline demographics, comorbidities, 4C mortality score (International Severe Acute Respiratory Infection Consortium-Comprehensive Clinical Characterization Collaboration [ISARIC-4C]), and COVID-19 vaccination status. Clinical and laboratory results, dyspnea by numerical rating scale, and palliative-related treatments were recorded at the first SPC review, when symptoms peaked, and the last SPC review. Patients with morphine equivalent daily dose (MEDD) of ≥45mg and/or BZD use for dyspnea control were grouped as high users, while patients with MEDD <45mg and no BZD use were low users. Results: Among 234 patients, 119 (50.9%) were high users. Multivariate analysis showed that subjects with higher dyspnea (odds ratio [OR] 1.74, 95% confidence interval [CI] 1.45-2.08) and lower ISARIC-4C scores (OR 0.77, 95% CI 0.67-0.88) at first SPC review were predictive of high users. High users also required higher supplemental oxygen and had higher inpatient mortality rates. Conclusions: High dyspnea score is predictive of high opioid and/or BZD use for symptom control in nonventilated patients with severe COVID-19. Such patients with high mortality rates should be seen early by SPC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
呼吸困难评分高是使用姑息治疗专家的触发因素--关于 COVID-19 患者大量使用阿片类药物和苯并二氮杂卓的队列研究结果。
背景:2019年严重冠状病毒病(COVID-19)患者通常会因严重呼吸困难而病情迅速恶化,应及早接受专科姑息治疗(SPC),因为在生命的最后阶段可能需要加强症状管理。目前,确定早期参与 SPC 的触发因素的数据很少。目的在需要大量使用阿片类药物和/或苯二氮卓类药物 (BZD) 控制呼吸困难的严重 COVID-19 非通气患者中识别风险因素。方法:这是一项回顾性队列研究:这是一项回顾性队列研究,研究对象是 2021 年 1 月至 2022 年 7 月期间在新加坡国家传染病中心住院并由 SPC 诊治的 COVID-19 非通风患者。我们收集了基线人口统计学资料、合并症、4C死亡率评分(国际严重急性呼吸道感染联盟-综合临床特征协作[ISARIC-4C])和COVID-19疫苗接种情况。在第一次 SPC 复查、症状达到高峰时和最后一次 SPC 复查时,记录了临床和实验室结果、呼吸困难数字评分表和姑息治疗相关情况。每日吗啡当量剂量(MEDD)≥45 毫克和/或使用 BZD 控制呼吸困难的患者被归类为高使用者,而每日吗啡当量剂量≥45 毫克和/或使用 BZD 控制呼吸困难的患者则被归类为低使用者:在 234 名患者中,119 人(50.9%)为高剂量使用者。多变量分析表明,首次 SPC 复查时呼吸困难程度较高(比值比 [OR] 1.74,95% 置信区间 [CI] 1.45-2.08)和 ISARIC-4C 评分较低(比值比 0.77,95% 置信区间 0.67-0.88)的受试者可预测为高使用者。高用户还需要更多的补充氧气,住院病人死亡率也更高。结论高呼吸困难评分可预测严重 COVID-19 非通气患者为控制症状而大量使用阿片类药物和/或 BZD 的情况。这类死亡率较高的患者应及早接受 SPC 检查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of palliative medicine
Journal of palliative medicine 医学-卫生保健
CiteScore
3.90
自引率
10.70%
发文量
345
审稿时长
2 months
期刊介绍: Journal of Palliative Medicine is the premier peer-reviewed journal covering medical, psychosocial, policy, and legal issues in end-of-life care and relief of suffering for patients with intractable pain. The Journal presents essential information for professionals in hospice/palliative medicine, focusing on improving quality of life for patients and their families, and the latest developments in drug and non-drug treatments. The companion biweekly eNewsletter, Briefings in Palliative Medicine, delivers the latest breaking news and information to keep clinicians and health care providers continuously updated.
期刊最新文献
Attitudes Toward Medical Assistance in Dying Among Swedish Palliative Care Professionals. Palliative Care and Intensivists' Different Perspectives on Specialist Palliative Care Engagement in Extracorporeal Membrane Oxygenation Care. Patterns of Specialty Palliative Consultation for Patients Admitted to Surgical Services. Letter to the Editor: "No-Shows" and Missed Opportunities: Reasons for Missed In-Person and Telehealth Appointments in an Ambulatory Palliative Care Program. What Matters to Older Native Hawaiians?: A Qualitative Study of Care Preferences.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1